Protocol for the 3HP Options Trial : a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda
BACKGROUND: Recently, a 3-month (12-dose) regimen of weekly isoniazid and rifapentine (3HP) was recommended by the World Health Organization for the prevention of tuberculosis (TB) among people living with HIV (PLHIV) on common antiretroviral therapy regimens. The best approach to delivering 3HP to PLHIV remains uncertain.
METHODS: We developed a three-armed randomized trial assessing optimized strategies for delivering 3HP to PLHIV. The trial will be conducted at the Mulago Immune Suppression Syndrome (i.e., HIV/AIDS) clinic in Kampala, Uganda. We plan to recruit 1656 PLHIV, randomized 1:1 to each of the three arms (552 per arm). Using a hybrid type 3 effectiveness-implementation design, this pragmatic trial aims to (1) compare the acceptance and completion of 3HP among PLHIV under three delivery strategies: directly observed therapy (DOT), self-administered therapy (SAT), and informed patient choice of either DOT or SAT (with the assistance of a decision aid); (2) to identify processes and contextual factors that influence the acceptance and completion of 3HP under each delivery strategy; and (3) to estimate the costs and compare the cost-effectiveness of three strategies for delivering 3HP. The three delivery strategies were each optimized to address key barriers to 3HP completion using a theory-informed approach. We hypothesize that high levels of treatment acceptance and completion can be achieved among PLHIV in sub-Saharan Africa and that offering PLHIV an informed choice between the optimized DOT and SAT delivery strategies will result in greater acceptance and completion of 3HP. The design and planned evaluation of the delivery strategies were guided by the use of implementation science conceptual frameworks.
DISCUSSION: 3HP-one of the most promising interventions for TB prevention-will not be scaled up unless it can be delivered in a patient-centered fashion. We highlight shared decision-making as a key element of our trial design and theorize that offering PLHIV an informed choice between optimized delivery strategies will facilitate the highest levels of treatment acceptance and completion.
TRIAL REGISTRATION: ClinicalTrials.gov: NCT03934931 ; Registered 2 May 2019.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Implementation science : IS - 15(2020), 1 vom: 12. Aug., Seite 65 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kadota, Jillian L [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 25.11.2021 Date Revised 16.07.2022 published: Electronic ClinicalTrials.gov: NCT03934931 Citation Status MEDLINE |
|---|
| doi: |
10.1186/s13012-020-01025-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313626545 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313626545 | ||
| 003 | DE-627 | ||
| 005 | 20231225150959.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13012-020-01025-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1045.xml |
| 035 | |a (DE-627)NLM313626545 | ||
| 035 | |a (NLM)32787925 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kadota, Jillian L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Protocol for the 3HP Options Trial |b a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.11.2021 | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT03934931 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Recently, a 3-month (12-dose) regimen of weekly isoniazid and rifapentine (3HP) was recommended by the World Health Organization for the prevention of tuberculosis (TB) among people living with HIV (PLHIV) on common antiretroviral therapy regimens. The best approach to delivering 3HP to PLHIV remains uncertain | ||
| 520 | |a METHODS: We developed a three-armed randomized trial assessing optimized strategies for delivering 3HP to PLHIV. The trial will be conducted at the Mulago Immune Suppression Syndrome (i.e., HIV/AIDS) clinic in Kampala, Uganda. We plan to recruit 1656 PLHIV, randomized 1:1 to each of the three arms (552 per arm). Using a hybrid type 3 effectiveness-implementation design, this pragmatic trial aims to (1) compare the acceptance and completion of 3HP among PLHIV under three delivery strategies: directly observed therapy (DOT), self-administered therapy (SAT), and informed patient choice of either DOT or SAT (with the assistance of a decision aid); (2) to identify processes and contextual factors that influence the acceptance and completion of 3HP under each delivery strategy; and (3) to estimate the costs and compare the cost-effectiveness of three strategies for delivering 3HP. The three delivery strategies were each optimized to address key barriers to 3HP completion using a theory-informed approach. We hypothesize that high levels of treatment acceptance and completion can be achieved among PLHIV in sub-Saharan Africa and that offering PLHIV an informed choice between the optimized DOT and SAT delivery strategies will result in greater acceptance and completion of 3HP. The design and planned evaluation of the delivery strategies were guided by the use of implementation science conceptual frameworks | ||
| 520 | |a DISCUSSION: 3HP-one of the most promising interventions for TB prevention-will not be scaled up unless it can be delivered in a patient-centered fashion. We highlight shared decision-making as a key element of our trial design and theorize that offering PLHIV an informed choice between optimized delivery strategies will facilitate the highest levels of treatment acceptance and completion | ||
| 520 | |a TRIAL REGISTRATION: ClinicalTrials.gov: NCT03934931 ; Registered 2 May 2019 | ||
| 650 | 4 | |a Clinical Trial Protocol | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Effectiveness-implementation hybrid | |
| 650 | 4 | |a HIV/AIDS | |
| 650 | 4 | |a Isoniazid | |
| 650 | 4 | |a Patient choice | |
| 650 | 4 | |a Person-centered care | |
| 650 | 4 | |a Preference trials | |
| 650 | 4 | |a Rifapentine | |
| 650 | 4 | |a Tuberculosis preventive therapy | |
| 650 | 7 | |a Antitubercular Agents |2 NLM | |
| 700 | 1 | |a Musinguzi, Allan |e verfasserin |4 aut | |
| 700 | 1 | |a Nabunje, Juliet |e verfasserin |4 aut | |
| 700 | 1 | |a Welishe, Fred |e verfasserin |4 aut | |
| 700 | 1 | |a Ssemata, Jackie L |e verfasserin |4 aut | |
| 700 | 1 | |a Bishop, Opira |e verfasserin |4 aut | |
| 700 | 1 | |a Berger, Christopher A |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Devika |e verfasserin |4 aut | |
| 700 | 1 | |a Sammann, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Katahoire, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Nahid, Payam |e verfasserin |4 aut | |
| 700 | 1 | |a Belknap, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Phillips, Patrick P J |e verfasserin |4 aut | |
| 700 | 1 | |a Namusobya, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Kamya, Moses |e verfasserin |4 aut | |
| 700 | 1 | |a Handley, Margaret A |e verfasserin |4 aut | |
| 700 | 1 | |a Kiwanuka, Noah |e verfasserin |4 aut | |
| 700 | 1 | |a Katamba, Achilles |e verfasserin |4 aut | |
| 700 | 1 | |a Dowdy, David |e verfasserin |4 aut | |
| 700 | 1 | |a Semitala, Fred C |e verfasserin |4 aut | |
| 700 | 1 | |a Cattamanchi, Adithya |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Implementation science : IS |d 2006 |g 15(2020), 1 vom: 12. Aug., Seite 65 |w (DE-627)NLM163016380 |x 1748-5908 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2020 |g number:1 |g day:12 |g month:08 |g pages:65 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13012-020-01025-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2020 |e 1 |b 12 |c 08 |h 65 | ||